Monday, 19 March 2012

ImmunoCellular to present at BIO-Europe Spring Conference in Amsterdam

Biotech firm ImmunoCellular (OTC:IMUC) announced Monday that Peter Ho will present at the Annual Partnering Conference in Amsterdam.
Ho, who is the company's director of business development and licensing, will be attending the Bio-Europe Spring convention on Tuesday, March 20, at 10:45 a.m. central European time.
The conference, which is taking place at the RAI Convention Centre in Amsterdam, offers life sciences companies promising partnering opportunities.
Last week, ImmunoCellular said that its proprietary method for making ICT-107, its dendritic cell-based vaccine for an aggressive type of brain cancer, showed better performance versus other methods for producing dendritic-based immunotherapies.
The company said its method has proven "meaningfully enhanced efficiency, consistency and convenience".
Manufacturing data showed its process can produce up to 30 vials of ICT-107 product and 30 vials of placebo in a single production run.
Developed in collaboration with the company’s partners, ImmunoCellular's manufacturing method uses a closed-bag system designed to produce highly potent dendritic cells from white blood cells collected from patients, and to preserve the cells for future vaccine treatments.
ImmunoCellular’s lead product candidate ICT-107 is currently in a randomized phase II trial at multiple centres in the U.S. ICT-107 is a dendritic cell-based vaccine that works by activating a patient's immune system against specific tumour associated antigens for glioblastoma multiforme, an aggressive type of brain cancer.
This is done by removing dendritic cells from a patient, loading them with the tumour-related antigens, and re-injecting them back into the patient's body to trigger an immune response against cancer cells exhibiting these antigens.
Rather than simply targeting a single tumour-specific antigen, ImmunoCellular's vaccine pursues multiple different antigens found on cancer stem cells.
Cancer stem cells are thought to be the originators of common tumour cells, and lead to cancer’s re-growth after chemotherapy. It is believed that destroying the cancer stem cells will allow for longer survival, without relapse.
The company, which is headquartered in Los Angeles, is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.

No comments:

Post a Comment